VivoSeq
Other

Second-Line Therapy

0

Pipeline Programs↗

7

Active Trials↗

5

Companies Involved↗

Second-line Therapy is an early-stage landscape with 0 programs across 5 companies. The most active players are Pfizer, Eli Lilly, Roche.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalEisai logo

Eisai

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Completed9 · 39%
Unknown status5 · 22%
Recruiting3 · 13%
Not yet recruiting3 · 13%
Terminated2 · 9%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

23 trials

Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
Recruiting·SShandong Cancer Hospital and Institute·Phase 3·NCT06841172·132 enrolled
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Recruiting·RReplimune Inc.·Phase 2·NCT05733598·60 enrolled
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Recruiting·—·Phase 1/2·NCT06202001·70 enrolled
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
Active, not recruiting·—·Phase 2·NCT03016871·78 enrolled
Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer
Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06904300·110 enrolled
Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC
Not yet recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·N/A·NCT07377916·60 enrolled
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
Not yet recruiting·RRui-hua Xu, MD, PhD·Phase 3·NCT06501664·360 enrolled
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
Completed·Pfizer logoPfizer·Phase 3·NCT00474786·512 enrolled
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT01282463·148 enrolled
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
Completed·IInstitut Curie·Phase 2·NCT00792025·80 enrolled
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT01737177·42 enrolled
Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens
Completed·TThe HIV Netherlands Australia Thailand Research Collaboration·Phase 4·NCT00627055·200 enrolled
Caffeic Acid Tablets as a Second-line Therapy for ITP
Completed·SShandong University·Phase 3·NCT02351622·103 enrolled
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Completed·Roche logoRoche·Phase 2·NCT00312728·115 enrolled
Europe-Africa Research Network for Evaluation of Second-line Therapy
Completed·—·Phase 3·NCT00988039·1,277 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)